Pfizer Inc. (FRA:PFE)
20.75
-0.07 (-0.31%)
May 27, 2025, 6:20 PM CET
Pfizer Revenue
Pfizer had revenue of $13.72B USD in the quarter ending March 30, 2025, a decrease of -7.82%. This brings the company's revenue in the last twelve months to $62.46B, up 11.65% year-over-year. In the year 2024, Pfizer had annual revenue of $63.63B with 6.84% growth.
Revenue (ttm)
$62.46B
Revenue Growth
+11.65%
P/S Ratio
2.03
Revenue / Employee
$771.16K
Employees
81,000
Market Cap
116.98B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Fresenius SE & Co. KGaA | 22.13B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
Pfizer News
- 1 day ago - Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates - Seeking Alpha
- 1 day ago - Stocks With the Highest Dividend Yields in the S&P 500 - Kiplinger
- 2 days ago - Notable healthcare headlines for the week: UnitedHealth, Pfizer and Medtronic in focus - Seeking Alpha
- 4 days ago - Pfizer Stock Analysis: Buy, Sell, or Hold? - The Motley Fool
- 4 days ago - FDA advisers recommend updating COVID shots to JN.1 strain - Seeking Alpha
- 4 days ago - Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Benzinga
- 4 days ago - Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - PRNewsWire
- 5 days ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga